Hypolipidemic Agents

27 Drugs classified under this therapeutic system

Omega-3 300 mg (DHA 120 mg, EPA 180 mg).
CAPS: 210. 1 cap dly, dur.
meal.
Nutritional supplement.
C/I: Hypersens.

Omega-3 600 mg.
CAPS: 120. 1-3 caps dly, dur. meal.
Nutritional supplement.
C/I: Hypersens.

Statin. Atorvastatin 10, 20, 40, 80 mg.
F.C. TABS: 30 x 10 mg, 20 mg, 40 mg, 80
mg. Prim. hypercholesterolem. incl.
famil. hypercholesterolem.
(heterozygous variant)/comb. (mixed)
hyperlipidemia (Fredrickson types IIa,
IIb): Initial: 10-20 mg 1 x dly. Pts. requir.
large reduct. in LDL (>45%): 40 mg 1 x
dly. Dos. range: 10-80 mg 1 x dly. To be
individualiz. Homozygous famil.
hypercholesterolem: 10-80 mg 1 x dly
as adjuv. to other lipid-lower. tmt or if
such tmts unavail. Heterozygous famil.
hypercholesterolem in ped. pts (10-17
yrs): Initial: 10 mg dly; max: 20 mg dly.
To be individualiz. Prevent. CV/
cerebrovasc. events: 10 mg dly. Higher
dos. may be necessary. Hepat. insuffic:
Perform liver tests bef. initiat. tmt, at 6
and 12 wks aft. initiat./elevat. dose and
periodic. (e.g. semi-annually). Ren.
insuffic: No dose adjust. req. Elderly: As
gen. populat.
Hypercholesterolem: Adjuv. to diet for
reduct. elevat. total cholesterol LDLcholesterol
apolipoprotein B and
triglycerides and to increase HDL
cholesterol in pts with prim.
hypercholesterolem. when response to
diet and other nonpharmacolog.
measures is inadeq; to reduce total-C and
LDL-C in pts. with homozygous familial
hypercholesterolem. as an adjunct to
other lipid-lower. tmt. (e.g. LDL apheres.)
or if such tmts are unavail. Ped. pts (10-17
yrs): Adjuv. to diet to reduce total -C, LDL-C
and apo B levels in boys and
postmenarchal girls with heterozygous
famil. hypercholesterolem. Prevent. CV
dis./cerebrovasc. event: Adjuv. to correct.
other risk factors such as hypertens. Pts.
with clinic. evident coronary heart dis:
Reduce risk of non-fatal MI; reduce risk of
fatal and non fatal stroke; reduce risk of
hospitalizat. for CHF; reduce risk of
angina. Reduce risk revascular. proced.
C/I: Hypersens., active liver dis./
unexplained persist. elevats. serum
transaminases exceeding 3 x upper limit
of normal; myopath., pregn./lact.;
women of childbear. potent. not using
approp. contracept. measures.

HMG-CoA Reductase Inhibitor, Lipid Modifying Agent. Ezetimibe 10 mg, Atorvastatin 10, 20, 40, 80 mg.
F.C. TABS.: 30. Hypercholesterolaemia and/or CHD with ACS History). The pt. should be on an appropriate lipid-lower. diet and should cont. on this diet during tmt. with this drug.
The dose range is 10/10 mg/d. through 10/80 mg/d. The typical dose is 10/10 mg ×1/d. The pt’s. low-density lipoprotein cholesterol (LDL-C) level, CHD status, and response to current cholesterol-lower. ther. should be consid. when starting ther. or adjust. the dose.
The dose should be individual. based on the known efficacy of the various dose strengths of and the response to the current cholesterol-lower. ther. Adjust. of dose should be made at intervals of 4 wks. or more.
HoFH: 10/10-10/80 mg dly. The drug  may be used as an adjunct to other lipid-lower. tmts. (e.g., LDL apheresis) in these pts. or if such tms. are unavailab.
May be taken with/without food.
Prevent. of Cardiovasc. Event: Indicat. to reduce the risk of cardiovasc. events in pts. with coron. heart dis.(CHD) and a hist. of acute coron. syndr. (ACS), either previous. treated with a statin or not.
Hypercholesterolaemia: The drug  indicat. as adjunct. ther. to diet for use in adult. with prim. (heterozygous famil. and non-famil.) hypercholesterolaemia or mixed hyperlipidaemia where use of a comb. product is appropriate, pts. not appropriat. control. with a statin alone, pts. already treated with a statin and ezetimibe.
Homozyg. Familial Hypercholesterolaemia (HoFH): Indicat. as adjunct. ther. to diet for use in adults with HoFH. Pts. may also receive adjunct. tmts. (e.g., low-density lipoprotein [LDL] apheresis).
C/I: Hypersens. Preg., lact. , and in women of child-bear. potent.

Fibrate. Bezafibrate 400 mg.
S.R. TABS: 30. 1 tab dly in even.
Hyperlipidem. in types 11a, 11b, III, IV, V
where diet alone is insuffic.
C/I: Hypersens., pregn., lact., liver/
gallbladder dis., severe renal funct.
disords.

Bile Acid Sequestrant. Colestipol HCl 5 gr.
PWDR: 50 packets x 5 g ea. 15-30 g dly.
in div. doses in 3 or more ounces of
liquid at least 1 hr. bef. or aft. taking
any other drug.
Adjunct ther. to diet in management
elevated cholesterol levels, hypercholesterolemia,
Fredrickson’s
type II
hyperlipoproteinemia.
C/I: Hypersens., compl. obstruct. biliary
tract.